Reporting and Study Data. Within three (3) months after the completion of the Final Study Report for the relevant Study, Company shall provide to CyDex a summary of the data and results of each Study that pertain solely to Captisol, and Company hereby grants to CyDex a non-exclusive, royalty-free license (with the right to sublicense) to use and disclose such data, including without limitation to update the DMF for Captisol.
Appears in 3 contracts
Samples: License and Supply Agreement (Melinta Therapeutics, Inc. /New/), License and Supply Agreement (Rib-X Pharmaceuticals, Inc.), License and Supply Agreement (Rib-X Pharmaceuticals, Inc.)
Reporting and Study Data. Within three (3) months after the completion receipt of the Final final Study Report report for the relevant a Study, Company shall provide to CyDex a summary of the data and results of each Study that pertain solely to Captisol, and subject to Section 8, Company hereby grants to CyDex a non-exclusivenonexclusive, royalty-free license (with the right to sublicense) to use and disclose such datadata (on a participant non-identifiable basis) solely as necessary for regulatory purposes, including without limitation to update the DMF for Captisol®.
Appears in 2 contracts
Samples: License Agreement (Ligand Pharmaceuticals Inc), License Agreement (Ligand Pharmaceuticals Inc)
Reporting and Study Data. Within three (3) months after the completion receipt of the Final final Study Report report for the relevant a Study, Company shall provide to CyDex a summary of the data and results of each Study that pertain solely to Captisol, and Company hereby grants to CyDex a non-exclusive, royalty-free license (with the right to sublicense) to use and disclose such datadata solely as necessary for regulatory purposes, including without limitation to update the DMF for Captisol®.
Appears in 1 contract
Reporting and Study Data. Within three (3) months after the completion receipt of the Final final Study Report report for the relevant a Study, Company shall provide to CyDex a summary of the data and results of each Study that pertain solely to Captisol, and subject to Section 8, Company hereby grants to CyDex a non-exclusive, royalty-free license (with the right to sublicense) to use and disclose such datadata solely as necessary for regulatory purposes, including without limitation to update the DMF for Captisol.
Appears in 1 contract
Samples: License Agreement (MEI Pharma, Inc.)
